Treatment of short-bowel syndrome.
The present article reviews the current literature on the role of diet and other trophic factors in the treatment of short-bowel syndrome. Results using glutamine, growth hormone and glucagon-like peptide 2 are reviewed. Although experimental animal data would suggest that various growth factors are of benefit in the treatment of short-bowel syndrome, only a few clinical studies have made the same claim.
Scolapio
J S
JS
Division of Gastroenterology, Mayo Clinic, Jacksonville, Florida 32224, USA. scolapio.james@mayo.edu
D000818:Animals; D003106:Colon / Q000502:physiology; D004040:Dietary Carbohydrates / Q000008:administration & dosage / Q000145:classification; D004195:Disease Models, Animal; D053767:Glucagon-Like Peptide 2; D004763:Glucagon-Like Peptides; D005973:Glutamine / Q000627:therapeutic use; D006133:Growth Substances / Q000627:therapeutic use; D006801:Humans; D007421:Intestine, Small / Q000637:transplantation; D010455:Peptides / Q000627:therapeutic use; D012778:Short Bowel Syndrome / Q000178:diet therapy / Q000601:surgery / Q000628:therapy*
D004040:Dietary Carbohydrates; D053767:Glucagon-Like Peptide 2; D006133:Growth Substances; D010455:Peptides; D005973:Glutamine; D004763:Glucagon-Like Peptides